NCT05011812View on ClinicalTrials.gov

Study of PBI-0451 in Healthy Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

August 14, 2021

Primary Completion Date

March 26, 2022

Study Completion Date

March 26, 2022

Conditions
Covid19
Interventions
DRUG

PBI-0451 Dose 1

Dose level 1 of PBI-0451

DRUG

PBI-0451 Dose 2

Dose level 2 of PBI-0451

DRUG

PBI-0451 Dose 3

Dose level 3 of PBI-0451

DRUG

PBI-0451 Dose 4

Dose level 4 of PBI-0451

DRUG

Ritonavir

Ritonavir will be co-administered with the study drug in Treatments J and K

DRUG

Midazolam

Midazolam will be co-administered with the study drug in Treatment L

DRUG

Placebo

Placebo to match

DRUG

PBI-0451

Dose level of PBI-0451 with a projected exposure

DRUG

PBI-0451 Dose 5

Dose level 5 of PBI-0451

Trial Locations (1)

1010

Auckland City Hospital, Auckland

Sponsors
All Listed Sponsors
lead

Pardes Biosciences, Inc.

INDUSTRY